secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001193125-25-157095
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Benitec Biopharma reports DSMB recommends continuation of BB-301 Phase 1b/2a study after Cohort 1
--------------------------------------------------------------------------------

- Sixth and final subject of Cohort 1 safely treated with low dose of BB-301 in April 2025.
- Independent DSMB reviewed all six Cohort 1 subjects and recommended continuation of enrollment.
- Enrollment of Cohort 2 expected to begin in Q4 2025 following positive DSMB recommendation.
- Additional clinical study updates for Cohort 1 subjects planned for Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525157095/0001193125-25-157095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525157095/d96075d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer